Publication: Multiple drug hypersensitivity
Issued Date
2017-05-01
Resource Type
ISSN
14230097
10182438
10182438
Other identifier(s)
2-s2.0-85015828040
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
International Archives of Allergy and Immunology. Vol.172, No.3 (2017), 129-138
Suggested Citation
Werner J. Pichler, Yuttana Srinoulprasert, James Yun, Oliver Hausmann Multiple drug hypersensitivity. International Archives of Allergy and Immunology. Vol.172, No.3 (2017), 129-138. doi:10.1159/000458725 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/42794
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Multiple drug hypersensitivity
Other Contributor(s)
Abstract
© 2017 The Author(s) Published by S. Karger AG, Basel. Multiple drug hypersensitivity (MDH) is a syndrome that develops as a consequence of massive T-cell stimulations and is characterized by long-lasting drug hypersensitivity reactions (DHR) to different drugs. The initial symptoms are mostly severe exanthems or drug rash with eosinophilia and systemic symptoms (DRESS). Subsequent symptoms due to another drug often appear in the following weeks, overlapping with the first DHR, or months to years later after resolution of the initial presentation. The second DHR includes exanthema, erythroderma, DRESS, Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN), hepatitis, and agranulocytosis. The eliciting drugs can be identified by positive skin or in vitro tests. The drugs involved in starting the MDH are the same as for DRESS, and they are usually given in rather high doses. Fixed drug combination therapies like sulfamethoxazole/trimethoprim or piperacillin/tazobactam are frequently involved in MDH, and 30-40% of patients with severe DHR to combination therapy show T-cell reactions to both components. The drug-induced T-cell stimulation appears to be due to the p-i mechanism. Importantly, a permanent T-cell activation characterized by PD-1+/CD38+ expression on CD4+/CD25lowT cells can be found in the circulation of patients with MDH for many years. In conclusion, MDH is a drug-elicited syndrome characterized by a long-lasting hyperresponsiveness to multiple, structurally unrelated drugs with clinically diverse symptoms.